Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Rodrigues

Showing results (181-190 of 199) with videos related to

Pageof 20
Sort By:
Cancers|August 26, 2022
Real-World Data on Newly Diagnosed <i>BRCA</i>-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME DatabaseMarta Bini, Stanislas Quesada, Pierre Meeus, et al.
Oncogene|September 11, 2021
The long non-coding RNA SAMMSON is essential for uveal melanoma cell survivalShanna Dewaele, Louis Delhaye, Boel De Paepe, et al.
Journal of the National Cancer Institute|December 7, 2023
Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variantsMarie-Charlotte Villy, Anaïs Le Ven, Marine Le Mentec, et al.
Future Oncology (London, England)|December 12, 2025
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2025
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
The New England Journal of Medicine|December 19, 2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerIsabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 19, 2025
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trialGuillaume Beinse, Karen Leroy, Pierre-Alexandre Just, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 TrialJean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, et al.
JAMA Ophthalmology|June 18, 2025
Uveal Melanoma and the Lynch Syndrome Tumor SpectrumAnaïs Le Ven, Marie-Charlotte Villy, André Bortolini Silveira, et al.
Pageof 20

Showing results (181-190 of 199) with videos related to

Sort By:
Pageof 20
Cancers|August 26, 2022
Real-World Data on Newly Diagnosed <i>BRCA</i>-Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME DatabaseMarta Bini, Stanislas Quesada, Pierre Meeus, et al.
Oncogene|September 11, 2021
The long non-coding RNA SAMMSON is essential for uveal melanoma cell survivalShanna Dewaele, Louis Delhaye, Boel De Paepe, et al.
Journal of the National Cancer Institute|December 7, 2023
Familial uveal melanoma and other tumors in 25 families with monoallelic germline MBD4 variantsMarie-Charlotte Villy, Anaïs Le Ven, Marine Le Mentec, et al.
Future Oncology (London, England)|December 12, 2025
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2025
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, et al.
The New England Journal of Medicine|December 19, 2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerIsabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 19, 2025
Association between molecular classification and overall survival in patients with metastatic endometrial carcinoma: ancillary results of the UTOLA phase II GINECO trialGuillaume Beinse, Karen Leroy, Pierre-Alexandre Just, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 29, 2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 TrialJean-Emmanuel Kurtz, Eric Pujade-Lauraine, Ana Oaknin, et al.
JAMA Ophthalmology|June 18, 2025
Uveal Melanoma and the Lynch Syndrome Tumor SpectrumAnaïs Le Ven, Marie-Charlotte Villy, André Bortolini Silveira, et al.
Pageof 20